Study S001531

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07670884
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 675
Start: 2026-07-24
Primary completion: 2027-10-31
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Chronic Management of Body Weight
Interventions: DRUG:HRS9531 Tablet; DRUG:HRS9531 Tablet Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percentage change from baseline in body weight after 52 weeks of treatment [After 52 weeks of treatment.]
Proportion of subjects with weight loss of ≥ 5% from baseline in body weight after 52 weeks of treatment [After 52 weeks of treatment.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.